Table 5.

Overall survival by patient characteristics, treatment and response groups, and muscle mass loss

Variable	Category	OR (95 % CI)	p value	aOR (95 % CI)a	p value
Age		1.02 (0.99–1.06)	0.21
Sex	Male	Ref	–	–	–
	Female	0.56 (0.31–1.02)	0.06	0.57 (0.28–1.17)	0.13
Race	White	Ref	–
	Non-White	0.83 (0.37–1.85)	0.65
Performance status	0	Ref	–
	1	0.95 (0.53–1.70)	0.86
	2	8.02 (0.95–67.4)	0.06
Statin use	No	Ref	–
	Yes	1.05 (0.56–1.96)	0.87
Baseline weight	<Median	Ref	–
	>Median	1.53 (0.87–2.69)	0.14
N:L ratio		1.05 (0.99–1.10)	0.11
IGF-1		1.00 (0.99–1.00)	0.17
CA 19-9 level		1.00 (0.99–1.00)	0.83
Albumin		0.26 (0.10–0.64)	0.004	0.26 (0.10–0.66)	0.005
Hemoglobin		0.94 (0.76–1.16)	0.56
Treatment group	MK	Ref	–	–	–
	Non-MK	1.84 (0.91–3.7)	0.09	2.05 (0.97–4.34)	0.06
Response group	PR	Ref	–	–	–
	SD	3.41 (1.58–7.39)	0.002	5.68 (2.48–13.01)	<0.001
	PD	2.96 (1.35–6.47)	0.007	3.86 (1.69–8.84)	0.001
Muscle mass loss at 2 months	≥6 cm2	Ref	–	Ref	–
	<6 cm2	0.51 (0.28–0.93)	0.03	0.41 (0.19–0.88)	0.02
Fat mass loss at 2 months	≥14.7 cm2	Ref	–
	<14.7 cm2	0.65 (0.33–1.27)	0.20

^aAdjusted hazard ratios are adjusted for sex, treatment group, response group, albumin at baseline, and muscle area loss